Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study
暂无分享,去创建一个
Susan M. Domchek | Fergus Couch | Kiley J. Johnson | F. Couch | S. Domchek | N. Lindor | Katherine Hunt | Noralane M. Lindor | V. Shane Pankratz | Hayden Harvey | Marcia Wilson | M. Cathie Smith | V. Shane Pankratz | Katherine S. Hunt | Marcia Wilson | Hayden Harvey | M. Cathie Smith
[1] E. Friedman,et al. Cancer risks among BRCA1 and BRCA2 mutation carriers , 2007, British Journal of Cancer.
[2] S. Fisher,et al. Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA) , 2003, Breast Cancer Research.
[3] G. Parmigiani,et al. Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations , 2004, European Journal of Human Genetics.
[4] J. Dowty,et al. Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of LAMBDA, BRCAPRO, Myriad II, and modified Couch models , 2007, Familial Cancer.
[5] M. Greene,et al. Concise handbook of familial cancer susceptibility syndromes - second edition. , 2008, Journal of the National Cancer Institute. Monographs.
[6] Betty J. Flehinger,et al. Colorectal cancer screening. , 1991, Journal of the National Cancer Institute.
[7] D. Berry,et al. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.
[8] M. Thun,et al. Performance of Common Genetic Variants in Breast-cancer Risk Models , 2022 .
[9] Sean V Tavtigian,et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Howell,et al. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family , 2008, BMC Cancer.
[11] M. Urioste,et al. The Average Cumulative Risks of Breast and Ovarian Cancer for Carriers of Mutations in BRCA1 and BRCA2 Attending Genetic Counseling Units in Spain , 2008, Clinical Cancer Research.
[12] J. P. Dunn. Colorectal cancer screening. , 1997, The New Zealand medical journal.
[13] D. Easton,et al. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families , 2005, Breast Cancer Research.
[14] R. Eeles,et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics , 2008, Journal of Medical Genetics.
[15] S. Gayther,et al. Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention , 2006, Acta obstetricia et gynecologica Scandinavica.
[16] Yun Yen,et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[17] Giovanni Parmigiani,et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Giovanni Parmigiani,et al. Meta-analysis of BRCA1 and BRCA2 penetrance. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] David W. Hosmer,et al. Applied Logistic Regression , 1991 .
[20] K. Offit,et al. Prevention and management of hereditary breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] F. Couch,et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.